De-escalation of tyrosine kinase inhibitor therapy is safe in chronic myeloid leukaemia in durable molecular response (&gt;= mr3 for &gt;= 12 months): initial results in the British DESTINY study

De-escalation of tyrosine kinase inhibitor therapy is safe in chronic myeloid leukaemia in durable molecular response (>= mr3 for >= 12 months): initial results in the British DESTINY study

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Author(s): Clark R, Polydoros F, Apperley J, Pocock C, Smith G, Salim R, Coffey T, O'Brien S, Foroni L, Copland M

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: 21st Congress of the European Hematology Association

Year of Conference: 2016

Pages: 60-60

Print publication date: 01/06/2016

Acceptance date: 02/04/2016

ISSN: 0390-6078

Publisher: Fondazione Ferrata Storti

URL: http://www.haematologica.org/content/101/s1/1

Series Title: Haematologica